Vivos Inc. Strives for Growth Amid Rising Costs and Regulatory Milestones in Oncology Market

Company Overview: Vivos Inc. (PINK: RDGL) is a radiation oncology medical device company focused on developing a precision radionuclide therapy device, **RadioGel™**, intended for treating non-resectable tumors.

Recent Developments:

• The company received FDA classification for RadioGel™ as a Breakthrough Device, facilitating a faster approval process.
• Vivos is pursuing clinical trials in India, having navigated various regulatory requirements for the same.
• Management has restructured operations focusing on both animal and human therapy, showcasing a strategic pivot to maximize market potential.

Income Statement Highlights:

• Revenues: Increased to $26,748 in Q1 2025 from $4,500 in Q1 2024. This represents a significant growth primarily driven by therapeutic services.
• Cost of Goods Sold: Increased to $35,831 in Q1 2025 from $6,000 in Q1 2024, contributing to a gross loss of $9,083 vs. $1,500 in Q1 2024.
• Operating Expenses: Rose to $854,449 in Q1 2025 from $575,629 in Q1 2024, reflecting heightened spending on professional fees, R&D, and general administrative costs.
• Net Loss: Increased to $834,696 in Q1 2025, from $558,539 in Q1 2024, highlighting the financial pressures due to elevated operational costs.
• Loss Per Share: Remains consistent at $(0.00) for both quarters, indicating continued deficits alongside share issuance adjustments.

Key Financial Statistics:

• Cash Position: $3,265,100 as of March 31, 2025.
• Working Capital: Grew to $3,186,489 as of Q1 2025 from $2,147,247 in Q4 2024.
• Common Stock Issued: Increased to 453,412,228 shares as of Q1 2025.
• Research and Development Costs: Jumped to $119,281 in Q1 2025 from $57,447 in Q1 2024, reflecting continued investment in product development.

Risk Factors and Concerns:

• Management acknowledges substantial doubt regarding the company's ability to sustain operations without additional funding.
• There is heavy reliance on external funding (approximately $3.0 million needed annually to maintain operations).
• Accumulated deficits continue to increase, suggesting ongoing challenges in achieving profitability.

Conclusion: Vivos Inc. is targeting significant growth through strategic initiatives but faces financial challenges. The increasing costs relative to revenue raise concerns about operational sustainability without securing sufficient capital.